Menopause and Hot Flashes.
Menopause is a natural change that occurs in a woman’s life when her ovaries stop producing estrogen and progesterone. Typically, this happens between the ages of 45 and 55. Menopause is generally defined as not having a period for 12 consecutive months. Hot flashes, which affect 80% of women, are one of the most common symptoms of menopause and can significantly disrupt a woman’s life.
Veozah, New Medication for Hot Flashes.
Mechanism of Action.
Veozah is a newly approved medication by the FDA to treat moderate to severe hot flashes. It is not a hormone but instead targets the neural activity responsible for hot flashes. By blocking the activity of the NK3 receptor, which controls the brain’s regulation of body temperature, Veozah effectively reduces hot flashes. Veozah 45 mg is taken orally once a day, with or without food, and is generally well tolerated.
Clinical trials involving women with an average age of 54, lasting around 52 weeks, have shown that Veozah effectively reduces the frequency and severity of hot flashes. In one study, women who took Veozah experienced an average of 50% fewer hot flashes compared to those who received a placebo.
Veozah has also demonstrated a favorable safety profile, with no reports of serious side effects. However, it is important to closely monitor liver enzymes during treatment. Additionally, Veozah should not be used with medications that inhibit CYP1A2, as they can excessively increase blood levels of Veozah. Examples of CYP1A2 inhibitors include fluvoxamine, clopidogrel, and montelukast.
Veozah offers a promising new treatment option for women with moderate to severe hot flashes. It is a safe and effective medication that can help women manage their symptoms and improve their overall quality of life.